Literature DB >> 17148557

Glucocorticoid response in amiodarone-induced thyrotoxicosis resulting from destructive thyroiditis is predicted by thyroid volume and serum free thyroid hormone concentrations.

Fausto Bogazzi1, Luigi Bartalena, Luca Tomisti, Giuseppe Rossi, Maria Laura Tanda, Enrica Dell'Unto, Fabrizio Aghini-Lombardi, Enio Martino.   

Abstract

CONTEXT: Amiodarone-induced thyrotoxicosis (AIT) resulting from destructive thyroiditis (type 2) is commonly treated with glucocorticoids, but time needed to restore euthyroidism may be unacceptable for patients with underlying cardiac disorders.
OBJECTIVE: The objective of this prospective study was to identify factors affecting the response to glucocorticoids in a large cohort of patients with type 2 AIT followed prospectively.
SETTING: This study was conducted at university centers. PATIENTS: Sixty-six untreated patients with type 2 AIT were enrolled in the study. INTERVENTION: All patients were treated with prednisone (initial dose, 0.5 mg/kg.d) as long as needed to restore euthyroidism, defined as cure of AIT. MAIN OUTCOME MEASURE: The main outcome measure was cure time.
RESULTS: The median cure time was 30 d (95% confidence interval, 23-37 d). Serum free T4 concentration (picograms per milliliter) and thyroid volume (milliliters per square meter) (and, to a lesser extent, serum free T3 concentration) at diagnosis were the main determinants of response to glucocorticoids, with a cure hazard ratio of 0.97 (95% confidence interval, 0.95-0.99; P = 0.005) and 0.84 (95% confidence interval, 0.77-0.91; P = 0.000) for unit of increment, respectively. AIT was cured in all patients with a complete follow-up; euthyroidism was reached in 30 d or less in 60% of patients but in more than 90 d in 16%. A prompt control of thyrotoxicosis (<or=30 d of treatment) was more frequent (77%) in patients with serum basal free T4 concentration no greater than 50 pg/ml and thyroid volume (normalized for body surface area) no greater than 12 ml/m2. The cure probability and the mean cure time in an individual patient can be obtained using a formula generated by multiple regression models.
CONCLUSIONS: Baseline serum thyroid hormone concentrations and thyroid volume help identify patients with type 2 AIT at risk of a delayed response to glucocorticoids.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17148557     DOI: 10.1210/jc.2006-2059

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  14 in total

1.  The presence of anti-thyroglobulin (TgAb) and/or anti-thyroperoxidase antibodies (TPOAb) does not exclude the diagnosis of type 2 amiodarone-induced thyrotoxicosis.

Authors:  L Tomisti; C Urbani; G Rossi; F Latrofa; C Sardella; L Manetti; I Lupi; C Marcocci; L Bartalena; O Curzio; E Martino; F Bogazzi
Journal:  J Endocrinol Invest       Date:  2016-01-13       Impact factor: 4.256

2.  Atrial fibrillation due to late amiodarone-induced thyrotoxicosis.

Authors:  Ibrahim Halil Kurt; Talat Yigit; Bulent Mustafa Karademir
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

3.  Thyroid gland: use of glucocorticoids in amiodarone-induced thyrotoxicosis.

Authors:  Mark P J Vanderpump
Journal:  Nat Rev Endocrinol       Date:  2009-12       Impact factor: 43.330

Review 4.  Amiodarone and the thyroid: a 2012 update.

Authors:  F Bogazzi; L Tomisti; L Bartalena; F Aghini-Lombardi; E Martino
Journal:  J Endocrinol Invest       Date:  2012-03-19       Impact factor: 4.256

5.  2018 European Thyroid Association (ETA) Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunction.

Authors:  Luigi Bartalena; Fausto Bogazzi; Luca Chiovato; Alicja Hubalewska-Dydejczyk; Thera P Links; Mark Vanderpump
Journal:  Eur Thyroid J       Date:  2018-02-14

6.  Amiodarone-induced destructive thyroiditis associated with coronary artery vasospasm and recurrent ventricular fibrillation.

Authors:  Matthew J Brooks; David A Pattison; Eliza P Teo; Sarah Price; Ronen Gurvitch
Journal:  Eur Thyroid J       Date:  2012-11-30

7.  Successful Pretreatment Using Plasma Exchange before Thyroidectomy in a Patient with Amiodarone-Induced Thyrotoxicosis.

Authors:  Annelies Tonnelier; Jeroen de Filette; Ann De Becker; Sophie Deweer; Brigitte Velkeniers
Journal:  Eur Thyroid J       Date:  2017-02-18

Review 8.  [Thyroid and treatment with amiodarone diagnosis, therapy and clinical management].

Authors:  Peter Mikosch
Journal:  Wien Med Wochenschr       Date:  2008

9.  Comparison of methimazole/hydrocortisone ointment with oral methimazole in patients with graves disease: A prospective, randomized, open-label, parallel-group, 18-month study.

Authors:  Ling Chen; Hong-Qing Wang; Yan-Yan Gao; Jun Liang; Men Wang; Jie Bai; Wen-Bo Qi; Jun-Sheng Zhang; Jian Zhang; Juan-Qing Ren; Hui-Qing Li
Journal:  Curr Ther Res Clin Exp       Date:  2008-08

10.  Amiodarone-induced thyrotoxic thyroiditis: a diagnostic and therapeutic challenge.

Authors:  Umang Barvalia; Barkha Amlani; Ram Pathak
Journal:  Case Rep Med       Date:  2014-11-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.